A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis
Ines Jeric1, Gabriele Maurer1, Anna Lina Cavallo1
1Department of Microbiology, Immune biology, and Genetics, Center for Molecular Biology, University of Vienna-Max F. Perutz Laboratories, Doktor-Bohr-Gasse 9, Vienna 1030, Austria.
Abstract:
Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths, but its molecular heterogeneity hampers the design of targeted therapies. Currently, the only therapeutic option for advanced HCC is Sorafenib, an inhibitor whose targets include RAF. Unexpectedly, RAF1 expression is reduced in human HCC samples. Modelling RAF1 downregulation by RNAi increases the proliferation of human HCC lines in xenografts and in culture; furthermore, RAF1 ablation promotes chemical hepatocarcinogenesis and the proliferation of cultured (pre)malignant mouse hepatocytes. The phenotypes depend on increased YAP1 expression and STAT3 activation, observed in cultured RAF1-deficient cells, in HCC xenografts, and in autochthonous liver tumours. Thus RAF1, although essential for the development of skin and lung tumours, is a negative regulator of hepatocarcinogenesis. This unexpected finding highlights the contribution of the cellular/tissue environment in determining the function of a protein, and underscores the importance of understanding the molecular context of a disease to inform therapy design.
Insights
RAF1, a protein typically linked to tumor suppression, unexpectedly promotes liver cancer (hepatocellular carcinoma) when its expression is reduced. This finding reveals RAF1 as a negative regulator of liver cancer, impacting targeted therapy design.
Area of Science:
- Oncology
- Molecular Biology
- Hepatology
Background:
- Hepatocellular carcinoma (HCC) is a major cause of cancer mortality.
- Molecular heterogeneity in HCC complicates targeted therapy development.
- Sorafenib, a RAF inhibitor, is the primary treatment for advanced HCC.
Purpose of the Study:
- To investigate the role of RAF1 in hepatocellular carcinoma (HCC) development.
- To understand the molecular mechanisms underlying RAF1's function in liver cancer.
Main Methods:
- RNA interference (RNAi) to model RAF1 downregulation in HCC cells.
- Xenograft and in vitro proliferation assays.
- Chemical induction of hepatocarcinogenesis in mice.
- Analysis of YAP1 and STAT3 activation.
Main Results:
- Reduced RAF1 expression in human HCC samples.
- RAF1 downregulation increased HCC cell proliferation in vitro and in vivo.
- RAF1 ablation promoted chemical hepatocarcinogenesis in mice.
- Phenotypes correlated with increased YAP1 expression and STAT3 activation.
Conclusions:
- RAF1 acts as a negative regulator of hepatocellular carcinoma (HCC).
- The function of RAF1 in cancer is context-dependent, influenced by the cellular environment.
- Understanding molecular context is crucial for designing effective HCC therapies.
More Related Videos
Related Concept Videos
The Ras Gene
Ras is a...
MAPK Signaling Cascades
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mutagenicity and Carcinogenicity


